Growth hormone for children with chronic kidney disease.

What It Covers

The paper reports a study of Exogenous HGH, sermorelin & older GHRPs (why they're passed over), published as a meta-analysis.

Growth retardation is a common complication of chronic kidney disease (CKD) in children and is of concern to families.

Recombinant human growth hormone (rhGH) treatment has been used to help short children with CKD attain a height more in keeping with their age group.

Who the Included Studies Covered

By PubMed's age tags, the people studied were infants, young children, children and teenagers.

How the Review Was Done

Randomised controlled trials (RCTs) were identified from the Cochrane Renal Group's Specialised Register, Cochrane Central Register of Controlled Trials (CENTRAL) (Issue 12, 2011), MEDLINE (from 1966), EMBASE (from 1980), article reference lists and through contact with local and international experts in the field.Date of last search: December 29, 2011.

What Was Measured

Two authors independently assessed studies for risk of bias and extracted data from eligible studies.

PubMed files the paper under topics including Body Height, Growth Disorders, Human Growth Hormone, Kidney Failure, Chronic, Randomized Controlled Trials as Topic and Recombinant Proteins.

What This Means in Plain Language

This is a meta-analysis of Exogenous HGH, sermorelin & older GHRPs (why they're passed over).

The abstract goes on to report its results in about 8 sentences; this page does not restate them, so read the paper for the findings and their limits.

The publication is from 2012 (The Cochrane database of systematic reviews), a journal based in England.

More context: the Exogenous HGH, sermorelin & older GHRPs (why they're passed over) compound page, all human trials.